All posts by: Michael Zand

About Michael Zand

Landmark Novartis Immunotherapy Faces Crucial FDA Hearing Wednesday – TheStreet.com

Continue reading

2017-07-12 NEWS

TheStreet.com

Landmark Novartis Immunotherapy Faces Crucial FDA Hearing Wednesday
TheStreet.com
The Oncologic Drugs Advisory Committee will examine the safety of CAR T-cell treatments, an immunotherapy manufactured by Novartis AG (NVS) for treatment of children and young adult leukemia patients who have not responded to traditional treatments.
Novartis readies for FDA review of $1 billion CAR-T child cancer hopeReuters UK
Novartis dodged deaths from its CAR-T Therapy, but FDA still has safety concernsLabiotech.eu (blog)
Novartis’ CAR-T Therapy for Pediatric Leukemia to Face FDA Advisory PanelAJMC.com Managed Markets Network

all 11 news articles »

Continue reading

2017-07-12 NEWS

Korea Biomedical Review

Ministry approves 1st domestic gene therapy product
Korea Biomedical Review
The Ministry of Food and Drug Safety said Wednesday it granted approval to Kolon’s gene therapy for knee osteoarthritis as the 29th domestically produced drug to gain approval and as the first of its kind.

Continue reading

2017-07-11 NEWS

Immunotherapy offers hope to lung cancer patients
Jakarta Post
Immunotherapy offers hope to lung cancer patients Courtesy of dongyminhngoc.org” width=”780″ height=”607″ border=”0″>Courtesy of dongyminhngoc.org. The prognosis of lung cancer patients remains the worst of all, with an average survival time of only …

Continue reading

2017-07-11 NEWS

Harvard Gazette

New approach may kill tumor cells in the brain
Harvard Gazette
Investigators from Brigham and Women’s Hospital (BWH) and the Harvard Stem Cell Institute (HSCI) may have discovered a way to kill tumor cells that have metastasized to the brain. The team has developed cancer-killing viruses that can deliver stem